1107 related articles for article (PubMed ID: 25948750)
21. IFI16 Partners with KAP1 to Maintain Epstein-Barr Virus Latency.
Xu H; Li X; Rousseau BA; Akinyemi IA; Frey TR; Zhou K; Droske LE; Mitchell JA; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2022 Sep; 96(17):e0102822. PubMed ID: 35969079
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells.
Ndour PA; Brocqueville G; Ouk TS; Goormachtigh G; Morales O; Mougel A; Bertout J; Melnyk O; Fafeur V; Feuillard J; Coll J; Adriaenssens E
J Virol; 2012 Apr; 86(7):3934-43. PubMed ID: 22258264
[TBL] [Abstract][Full Text] [Related]
23. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.
Prince S; Keating S; Fielding C; Brennan P; Floettmann E; Rowe M
J Virol; 2003 Apr; 77(8):5000-7. PubMed ID: 12663807
[TBL] [Abstract][Full Text] [Related]
24. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
25. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
26. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.
Goormachtigh G; Ouk TS; Mougel A; Tranchand-Bunel D; Masy E; Le Clorennec C; Feuillard J; Bornkamm GW; Auriault C; Manet E; Fafeur V; Adriaenssens E; Coll J
J Virol; 2006 Aug; 80(15):7382-93. PubMed ID: 16840319
[TBL] [Abstract][Full Text] [Related]
27. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr Virus Latent Membrane Protein-1 Induces the Expression of SUMO-1 and SUMO-2/3 in LMP1-positive Lymphomas and Cells.
Salahuddin S; Fath EK; Biel N; Ray A; Moss CR; Patel A; Patel S; Hilding L; Varn M; Ross T; Cramblet WT; Lowrey A; Pagano JS; Shackelford J; Bentz GL
Sci Rep; 2019 Jan; 9(1):208. PubMed ID: 30659232
[TBL] [Abstract][Full Text] [Related]
30. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency.
Bentz GL; Lowrey AJ; Horne DC; Nguyen V; Satterfield AR; Ross TD; Harrod AE; Uchakina ON; McKallip RJ
PLoS One; 2019; 14(5):e0217578. PubMed ID: 31125383
[TBL] [Abstract][Full Text] [Related]
31. The Epstein-Barr Virus Oncoprotein, LMP1, Regulates the Function of SENP2, a SUMO-protease.
Selby TL; Biel N; Varn M; Patel S; Patel A; Hilding L; Ray A; Ross T; Cramblet WT; Moss CR; Lowrey AJ; Bentz GL
Sci Rep; 2019 Jul; 9(1):9523. PubMed ID: 31266997
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus downregulates microRNA 203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells.
Yu H; Lu J; Zuo L; Yan Q; Yu Z; Li X; Huang J; Zhao L; Tang H; Luo Z; Liao Q; Zeng Z; Zhang J; Li G
J Virol; 2012 Mar; 86(6):3088-99. PubMed ID: 22205737
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.
Motsch N; Pfuhl T; Mrazek J; Barth S; Grässer FA
RNA Biol; 2007 Nov; 4(3):131-7. PubMed ID: 18347435
[TBL] [Abstract][Full Text] [Related]
34. Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells.
Sung WW; Chu YC; Chen PR; Liao MH; Lee JW
Cancer Lett; 2016 Nov; 382(1):21-31. PubMed ID: 27567526
[TBL] [Abstract][Full Text] [Related]
35. PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.
Lupey-Green LN; Caruso LB; Madzo J; Martin KA; Tan Y; Hulse M; Tempera I
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976663
[TBL] [Abstract][Full Text] [Related]
36. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.
Hagemeier SR; Dickerson SJ; Meng Q; Yu X; Mertz JE; Kenney SC
J Virol; 2010 May; 84(9):4383-94. PubMed ID: 20181712
[TBL] [Abstract][Full Text] [Related]
37. Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1.
Hurwitz SN; Cheerathodi MR; Nkosi D; York SB; Meckes DG
J Virol; 2018 Mar; 92(5):. PubMed ID: 29212935
[TBL] [Abstract][Full Text] [Related]
38. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
40. Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus.
Chau CM; Lieberman PM
J Virol; 2004 Nov; 78(22):12308-19. PubMed ID: 15507618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
